Form 4 for EW Edwards Lifesciences
Accepted 2026-02-26 00:00:00 ET · period of report 2026-02-25 · accession 0001225208-26-002711 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-26 | 2026-02-25 | EW | BOBO DONALD E JR | CVP, Strategy, Corp Development | S - Sale | $83.84 | -24.0K | 21.3K | -53% | -$2.01M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-25 | S | D | 24,000 | $83.84 | 21,266.25 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $83.66 to $83.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. (F2) Total reflects the correction of 13,396 shares held indirectly by the Reporting Person's trust, which were previously reported as directly held. |